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Introduction: Previous work has demonstrated the efficacy of irradiating tissue with red to infrared light in
mitigating cerebral pathology and degeneration in animal models of stroke, traumatic brain injury, parkinsonism
and Alzheimer’s disease (AD). Using mouse models, we explored the neuroprotective effect of near infrared light
(NIr) treatment, delivered at an age when substantial pathology is already present in the cerebral cortex.
Methods: We studied two mouse models with AD-related pathologies: the K369I tau transgenic model (K3),
engineered to develop neurofibrillary tangles, and the APPswe/PSEN1dE9 transgenic model (APP/PS1), engineered to
develop amyloid plaques. Mice were treated with NIr 20 times over a four-week period and histochemistry was used to
quantify AD-related pathological hallmarks and other markers of cell damage in the neocortex and hippocampus.
Results: In the K3 mice, NIr treatment was associated with a reduction in hyperphosphorylated tau, neurofibrillary
tangles and oxidative stress markers (4-hydroxynonenal and 8-hydroxy-2′-deoxyguanosine) to near wildtype levels in
the neocortex and hippocampus, and with a restoration of expression of the mitochondrial marker cytochrome c
oxidase in surviving neurons. In the APP/PS1 mice, NIr treatment was associated with a reduction in the size and number
of amyloid-β plaques in the neocortex and hippocampus.
Conclusions: Our results, in two transgenic mouse models, suggest that NIr may have potential as an effective,
minimally-invasive intervention for mitigating, and even reversing, progressive cerebral degenerations.Introduction
Alzheimer’s disease (AD) is a chronic, debilitating neuro-
degenerative disease with limited therapeutic options; at
present there are no treatments that prevent the physical
deterioration of the brain and the consequent cognitive
deficits. Histopathologically, AD is characterised by neuro-
fibrillary tangles (NFTs) of hyperphosphorylated tau pro-
tein and amyloid-beta (Aβ) plaques [1,2]. The extent of
these histopathological features is considered to vary with
and to determine clinical disease severity [2]. While the* Correspondence: Daniel.Johnstone@sydney.edu.au
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bated, there is strong evidence to suggest that oxidative
stress and mitochondrial dysfunction have important roles
in the neurodegenerative cascade [3-5]. Therefore, it has
been proposed that targeting mitochondrial dysfunction
could prove valuable for AD therapeutics [6].
One safe, simple yet effective approach to the repair of
damaged mitochondria is photobiomodulation with
near-infrared light (NIr). This treatment, which involves
the irradiation of tissue with low intensity light in the
red to near-infrared wavelength range (600 to 1000 nm),
was originally pioneered for the healing of superficial
wounds [7] but has been recently shown to have efficacy
in protecting the central nervous system. While the
mechanism of action remains to be elucidated, there isCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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by reversing dysfunctional mitochondrial cytochrome c
oxidase (COX) activity, thereby mitigating the production
of reactive oxygen species and restoring ATP production
to normal levels [8,9].
To date, NIr treatment has yielded neuroprotective
outcomes in animal models of retinal damage [9,10],
traumatic brain injury [11,12], Parkinson’s disease [13-15]
and AD [16,17]. Furthermore, NIr therapy has yielded
beneficial outcomes in clinical trials of human patients
with mild to moderate stroke [18] and depression [19].
This treatment represents a promising alternative to
drug therapy because it is safe, easy to apply and has no
known side-effects at levels even higher than optimal
doses [20].
The aim of this study was to assess the efficacy of NIr
in mitigating the brain pathology and associated cellular
damage that characterise AD. We utilised two mouse
models, each manifesting distinct AD-related patholo-
gies: the K3 tau transgenic model, which develops NFTs
[21,22]; and the APP/PS1 transgenic model, which de-
velops amyloid plaques [23]. Here, we present histo-
chemical evidence that NIr treatment over a period of 1
month reduces the severity of AD-related pathology and
oxidative stress and restores mitochondrial function in
brain regions susceptible to neurodegeneration in AD,
specifically the neocortex and hippocampus. The find-
ings extend our previous NIr work in models of acute
neurodegeneration [13,14] to demonstrate that NIr is
also effective in protecting the brain against chronic in-
sults due to AD-related genetic aberrations, a pathogenic




The K3 transgenic mouse model, originally generated as a
model of frontotemporal dementia [21,22], harbours a hu-
man tau gene with the pathogenic K369I mutation; expres-
sion is driven by the neuron-specific mThy1.2 promoter.
This model manifests high levels of hyperphosphorylated
tau and NFTs by 2 to 3 months of age and cognitive defi-
cits by about 4 months of age [21,22]. We commenced our
experiments on K3 mice and matched C57BL/6 wildtype
(WT) controls at 5 months of age, when significant neuro-
pathology is already present.
The APPswe/PSEN1dE9 (APP/PS1) transgenic mouse
model, obtained from the Jackson Laboratory (Stock num-
ber 004462; Bar Harbor, ME, USA), harbours two human
transgenes: the amyloid beta precursor protein gene (APP)
containing the Swedish mutation; and the presenilin-1
gene (PS1) containing a deletion of exon 9 [23]. The APP/
PS1 mice exhibit increased Aβ and amyloid plaques by 4
months of age [24] and cognitive deficits by 6 months ofage [25]. We commenced our experiments on APP/PS1
mice and matched C57BL/6 × C3H WT controls at 7
months of age, when numerous amyloid plaques and as-
sociated cognitive deficits are present.
Genotyping of mice was achieved by extracting DNA
from tail tips through a modified version of the Hot
Shot preparation method [26] and amplifying the
transgene sequence by polymerase chain reaction. As
reported previously, K3 mice were identified using the
primers 5′-GGGTGTCTCCAATGCCTGCTTCTTCAG-3′
(forward) and 5′-AAGTCACCCAGCAGGGAGGTGC
TCAG-3′ (reverse) [21,22] and APP/PS1 mice were ge-
notyped using primers 5′-AGGACTGACCACTCGAC-
CAG-3′ (forward) and 5′-CGGGGGTCTAGTTCTGC
AT-3′ (reverse) [23].
Experimental design
For each series of experiments on K3 mice (aged 5 months)
or APP/PS1 mice (aged 7 months) there were three
experimental groups: untreated WT mice, untreated
transgenic mice and NIr-treated transgenic mice (n = 5
mice per experimental group for the K3 series, 15 mice
in total; n = 6 mice per experimental group for the APP/
PS1 series, 18 mice in total). Our design did not include
a WT control group exposed to NIr because NIr has no
detectable impact on the survival and function of cells
in normal healthy brain [13-15]. Given the consistency
of the previous results, use of animals for this extra
control group did not seem justified [27].
Mice in the NIr-treated groups were exposed to one
90-second cycle of NIr (670 nm) from a light-emitting
device (LED) (WARP 10; Quantum Devices, Barneveld,
WI, USA) for 5 days per week over 4 consecutive weeks.
Light energy emitted from the LED during each 90-
second treatment equates to 4 Joule/cm2; a total of 80
Joule/cm2 was delivered to the skull over the 4 weeks.
Our measurements of NIr penetration across the fur and
skull of a C57BL/6 mouse indicate that ~2.5% of trans-
mitted light reaches the cortex.
For each treatment, the mouse was restrained by hand
and the LED was held 1 to 2 cm above the head. The
LED light generated no heat and reliable delivery of the
radiation was achieved [13-15]. For the sham-treated
WT, K3 and APP/PS1 groups, animals were restrained
in the same way and the device was held over the head,
but the light was not switched on. This treatment regime
is similar to that used in previous studies where bene-
ficial changes to neuropathology and behavioural signs
were reported [13-15].
Experimental animals were housed two or more to a
cage and kept in a 12-hour light (<5 lux)/dark cycle at
22°C; food pellets and water were available ad libitum.
All protocols were approved by the Animal Ethics
Committee of the University of Sydney.
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At the end of the experimental period, mice were anaes-
thetised by intraperitoneal injection of sodium pentobar-
bital (60 mg/kg) and perfused transcardially with 4%
buffered paraformaldehyde. Brains were post fixed for 3
hours, washed with phosphate-buffered saline and cryopro-
tected in 30% sucrose/phosphate-buffered saline. Tissue was
embedded in OCT compound (ProSciTech, Thuringowa,
QLD, Australia) and coronal sections of the neocortex and
the hippocampus (between bregma −1.8 and −2.1) were cut
at 20 μm thickness on a Leica cryostat (Nussloch, Germany).
Immunohistochemistry
For most antibodies, antigen retrieval was achieved using
sodium citrate buffer with 0.1% Triton. Sections were
blocked in 10% normal goat serum and then incubated
overnight at 4°C with a mouse monoclonal antibody –
paired helical filaments-tau AT8, 1:500 (Innogenetics,
Ghent, Belgium); 4-hydroxynonenal (4-HNE), 1:200 (JaICA,
Fukuroi, Shizuoka, Japan); 8-hydroxy-2′-deoxyguanosine
(8-OHDG), 1:200 (JaICA); COX, 1:200 (MitoSciences,
Eugene, OR, USA) – and/or a rabbit polyclonal antibody
(200 kDa neurofilament, 1:500; Sigma, St. Louis, MO,
USA). Sections were then incubated for 3 hours at room
temperature in Alexa Fluor-488 (green) and/or Alexa
Fluor-594 (red) tagged secondary antibodies specific to host
species of the primary antibodies (1:1,000; Molecular
Probes, Carlsbad, CA, USA). Sections were then counter-
stained for nuclear DNA with bisbenzimide (Sigma).
Two different but complementary antibodies were used
to label Aβ peptide: 6E10, which recognises residues 1 to
16; and 4G8, which recognises residues 17 to 24. We have
previously used these two antibodies in combination to val-
idate Aβ labelling, demonstrating identical labelling pat-
terns in the rat neocortex and hippocampus [28]. For
double labelling using 6E10 antibodies (1:500; Covance,
Princeton, NJ, USA) and anti-glial fibrillary acidic protein
antibodies (1:1,000; DAKO, Glostrup, Denmark), antigen
retrieval was achieved by incubation in 90% formic acid for
10 minutes, and primary antibody incubation was carried
out overnight at room temperature. For labelling using the
4G8 (1:500; Covance) antibody, slides were treated with 3%
H2O2 in 50% methanol, incubated in 90% formic acid and
then washed several times in dH2O before the blocking
step, as described previously [28]. After blocking, sections
were incubated overnight at room temperature with 4G8
antibody. Sections were then incubated in biotinylated goat
anti-mouse IgG for 1 hour followed by ExtrAvidin peroxid-
ase for 2.5 hours. The sections were then washed and
developed with 3,3′-Diaminobenzidine.
Negative control sections were processed in the same
fashion as described above except that primary anti-
bodies were omitted. These control sections were immu-
nonegative. Fluorescent images were taken using a ZeissApotome 2, Carl Zeiss, Oberkochen, Germany. Bright-
field images were taken using a Nikon Eclipse E800,
Nikon Instruments, Melville, NY, USA.
Histology
NFTs were assessed using the Bielschowsky silver staining
method, as described previously [21,22]. Briefly, sections
were placed in prewarmed 10% silver nitrate solution for 15
minutes, washed and then placed in ammonium silver ni-
trate solution at 40°C for a further 30 minutes. Sections
were subsequently developed for 1 minute and then trans-
ferred to 1% ammonium hydroxide solution for 1 minute
to stop the reaction. Sections were then washed in dH2O,
placed in 5% sodium thiosulphate solution for 5 minutes,
washed, cleared and mounted in dibutyl phathalate xylene.
As described previously [28], Aβ plaques were studied
by staining with Congo red, a histological dye that binds
preferentially to compacted amyloid with a β-sheet sec-
ondary structure [29]. Briefly, sections were treated with
2.9 M sodium chloride in 0.01 M NaOH for 20 minutes
and were subsequently stained in filtered alkaline 0.2%
Congo red solution for 1 hour.
Morphological analysis
Staining intensity and area measurements
To quantify the average intensity and area of antibody
labelling within the neocortex and hippocampal regions,
an integrated morphology analysis was undertaken using
MetaMorph software. For each section, the level of non-
specific staining (using an adjacent region of unstained
midbrain) was adjusted to a set level to ensure a stand-
ard background across different groups. Next, outlines
of retrosplenial cortex area 29 and hippocampal CA1 re-
gion were traced and the average intensity and area of
immunostaining were calculated by the program. Mea-
surements were conducted on ≥4 representative sections
per animal and ≥3 animals per experimental group. Statis-
tical analyses were performed in Prism 5.0 (Graphpad, La
Jolla, CA, USA) using one-way analysis of variance with
Tukey’s multiple comparison post test. All values are given
as mean ± standard error of mean.
Amyloid-beta plaque measurements
Digital brightfield images of 4G8 staining in the neocortical
and hippocampal regions (between bregma −1.8 and −2.1)
were taken at 4× magnification and analysed with Meta-
morph, Molecular Devices LLC, Sunnyvale, CA, USA. The
software was programmed to measure the number of pla-
ques and the average size of plaques after thresholding for
colour. The percentage of area covered by plaques (plaque
burden) was calculated by multiplying the number of pla-
ques by the average size of plaques, divided by the area of
interest, as described previously [30]. The average number
of Congo red-positive plaques in the APP/PS1 brain
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method (StereoInvestigator; MBF Science, Williston, VT,
USA), as outlined previously [14]. Briefly, systematic ran-
dom sampling of sites was undertaken using an un-
biased counting frame (100 μm× 100 μm). All plaques
that came into focus within the frame were counted. Mea-
surements were conducted on ≥4 representative sections
per animal and ≥3 animals per experimental group. Plaque
numbers and size were analysed using a two-tailed un-
paired t test (when variances were equal) or Welch’s t test
(when variances were unequal). All values are given as
mean ± standard error of mean. For all analyses, investiga-
tors were blinded to the experimental groups.Results
Evidence of NIr-induced neuroprotection is presented
from the neocortex (retrosplenial area) and the hippo-
campus (CA1 and subiculum), two cortical regions af-
fected in the early stages of human AD [2].Figure 1 Time course of the natural development of cortical patholog
hyperphosphorylated tau labelling (red), using the AT8 antibody, in the neo
months (A, D), 6 months (B, E) and 12 months (C, F) of age. (G), (H), (I) Micr
in neocortex of untreated APP/PS1 mice at 3 months (G), 4.5 months (H) and
arrows indicate extracellular plaques. Comparable immunolabelling was achie
acidic protein (red), a marker of astrocytes. For all sections, nuclei were labelleNear-infrared light mitigates the tau pathology of K3 cortex
Hyperphosphorylation of the neuronal microtubule sta-
bilising protein tau and the resulting NFTs are much
studied features of dementia pathology [2,31]. The K3
mouse model manifests hyperphosphorylated tau and
NFTs by 2 to 3 months of age and cognitive deficits by
about 4 months of age [21,22]. We observe strong label-
ling for hyperphosphorylated tau in the neocortex and
the hippocampus at 6 months of age; expression appears
to plateau after this age, with similar labelling observed
in 12-month-old mice (Figure 1A,B,C,D,E,F).
In the retrosplenial area of the neocortex there was a
significant overall difference in AT8 immunolabelling for
tau between the experimental groups, both when consid-
ering average intensity of labelling (P < 0.01 by analysis
of variance; Figure 2A) and labelled area (P < 0.01;
Figure 2B). Tukey post hoc testing revealed significant
differences between the untreated K3 group and the
other two groups; labelling was much stronger and more
widespread in K3 mice than WT controls (17-fold highery in K3 and APP/PS1 mice. (A), (B), (C), (D), (E), (F) Micrographs of
cortex (A to C) and hippocampus (D to F) of untreated K3 mice at 3
ographs of amyloid-beta (Aβ) labelling (green), using the 6E10 antibody,
12 months (I) of age. Arrowheads indicate intraneuronal Aβ labelling,
ved with the 4G8 antibody. Sections were co-labelled for glial fibrillary
d with bisbenzimide (blue). Scale in (H) applies to (A) to (G).
Figure 2 Effect of near-infrared light treatment on hyperphosphorylated tau and neurofibrillary tangles in the neocortex of K3 mice.
(A), (B) Quantification of tau AT8 immunolabelling, based on average labelling intensity (A) and labelled area (B). All error bars indicate standard
error of mean. *P < 0.05, **P < 0.01. (C), (D), (E) Representative photomicrographs of sections stained with Bielschowsky silver stain to demonstrate
neurofibrillary tangles (NFTs). Arrows indicate axonal swellings and NFTs. (F), (G), (H) Representative micrographs of AT8 (red) labelling within neurons
of the neocortex retrosplenial area. Nuclei were labelled with bisbenzimide (blue). Scale bars = 50 μm; scale in (E) applies to (C) and (D), scale in (H)
applies to (F) and (G). NIr, near-infrared light; WT, wildtype.
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over 70% in NIr-treated mice (P < 0.05). Interestingly,
there was no significant difference between the WT
and K3-NIr groups, suggesting that NIr treatment had
reduced hyperphosphorylated tau to control levels in K3
mice. A similar trend was observed when considering the
NFT pathology (Figure 2C,D,E). In contrast to WT brain,which showed no NFT-like lesions (Figure 2C), the K3
brain contained many ovoid shaped NFT-like lesions (that
is, spheroids; Figure 2D). Such structures were less fre-
quent in the K3-NIr brain (Figure 2E).
Similar effects were observed in the hippocampus
(Figure 3). There was a significant overall difference be-
tween the experimental groups in AT8 immunolabelling
Figure 3 Effect of near-infrared light treatment on hyperphosphorylated tau and neurofibrillary tangles in the hippocampus of K3
mice. (A), (B) Quantification of tau AT8 immunolabelling, based on average labelling intensity (A) and labelled area (B). All error bars indicate
standard error of mean. **P < 0.01, ***P < 0.001. (C), (D), (E) Representative photomicrographs of sections of the hippocampal subiculum area,
stained with Bielschowsky silver stain to demonstrate neurofibrillary tangles (NFTs). Arrows indicate axonal swellings and NFTs. The classical silver
stain also labelled axons in the white matter core (WM). (F), (G), (H) Representative micrographs of AT8 (red) labelling within hippocampal CA1
pyramidal neurons. Nuclei were labelled with bisbenzimide (blue). Scale bars = 50 μm; scale in (E) applies to (C) and (D), scale in (H) applies to
(F) and (G). NIr, near-infrared light; WT, wildtype.
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cortex, K3 mice showed far greater labelling than WT
mice (17-fold higher intensity, P < 0.01) and this was
reduced over 65% by NIr treatment (P < 0.01). Again,
there were no significant differences between the WT
and K3-NIr groups (P > 0.05). Bielschowsky silver
staining of the subiculum (Figure 3C,D,E) revealed
axonal swellings and spheroids in the hippocampal
region of K3 mice (Figure 3D), which were less pro-
nounced in mice from the K3-NIr group (Figure 3E).
No pathology was observed in the hippocampus of WT
mice (Figure 3C).One should note that the large white matter pathways
associated with the hippocampus were labelled intensely
by silver staining in all three groups (Figure 3C,D,E).
This labelling has been described previously and is not
associated with any neuropathology [32].
Near-infrared light reduces oxidative stress in K3 cortex
Oxidative stress and damage are common features of
neurodegenerative diseases such as AD, and may be a
precursor to neuronal death [3-5]. We assessed two
common markers of oxidative stress: 4-HNE, a toxic
end-product of lipid peroxidation that may bind to
Figure 4 Effect of near-infrared light treatment on oxidative stress markers in the neocortex of K3 mice. (A), (B), (F), (G) Quantification
of immunolabelling of two oxidative stress markers, 4-hydroxynonenal (4-HNE; A, B) and 8-hydroxy-2′-deoxyguanosine (8-OHDG; F, G), based on
average labelling intensity (A, F) and labelled area (B, G). All error bars indicate standard error of the mean. *P < 0.05, **P < 0.01, ***P < 0.001. (C),
(D), (E), (H), (I), (J) Representative micrographs of 4-HNE (red) labelling (C, D, E) and 8-OHDG (red) labelling (H, I, J) within layers IV and V of the
neocortical retrosplenial area. Nuclei were labelled with bisbenzimide (blue). Scale bar = 50 μm; scale in (J) applies to all other micrographs. NIr,
near-infrared light; WT, wildtype.
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cellular apoptosis in AD [33]; and 8-OHDG, a marker
for nuclear and mitochondrial DNA oxidation, which is
elevated in AD brains [34].Overall, 4-HNE immunoreactivity in the neocortex
was significantly different between the experimental
groups (Figure 4), by both average labelling intensity
(P < 0.01) and labelled area (P < 0.001). As with AT8
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average 4-HNE labelling intensity and area than the
WT group (fivefold and 20-fold, respectively) and this
labelling was significantly reduced (by 50% and 80%,
respectively) in the K3-NIr group. Again, these mea-
sures showed no significant differences between the
WT and K3-NIr groups (P > 0.05).
Similar patterns were observed for 8-OHDG immunore-
activity. Overall, there was a significant difference between
the groups for 8-OHDG immunolabelling, by both average
intensity (P < 0.0001) and labelled area (P < 0.0001). Again
the K3 group showed significantly higher 8-OHDG labelling
intensity and area than the WT group (sixfold and 17-fold,
respectively), and the 8-OHDG labelling intensity and area
were significantly reduced in the K3-NIr group relative to
untreated K3 (65% and 85% reduction, respectively). The in-
tensity and area of 8-OHDG labelling did not differ signifi-
cantly between the WT and the K3-NIr groups (P > 0.05),
suggesting that NIr treatment reduces markers of oxidative
stress to control levels. The representative photomicro-
graphs of 8-OHDG immunoreactivity in the retrosplenial
area (Figure 4H,I,J) reflect the quantitative data, with many
8-OHDG+ structures in the K3 group (Figure 4I) but not in
the WTand K3-NIr groups (Figure 4H,J).
Near-infrared light mitigates mitochondrial dysfunction in
K3 cortex
We assessed expression patterns of the mitochondrial
enzyme COX in the neocortex and the hippocampus as
a marker of mitochondrial function. Overall, there were
statistically significant differences in the patterns of COX
immunoreactivity between the different experimental
groups, both in the neocortex and the hippocampus (both
P < 0.0001; Figure 5). Relative to WT mice, the COX label-
ling intensity and area were reduced in K3 mice in both
the neocortex and the hippocampus (>70% and >75%
reductions, respectively). The K3-NIr mice showed a
significant recovery of COX immunoreactivity relative
to untreated K3 mice in both the neocortex (>1.7-fold
increase, P < 0.05) and the hippocampus (>3.4-fold in-
crease, P < 0.001). However, recovery was not complete,
with K3-NIr mice having significantly lower COX im-
munoreactivity than WT mice in the neocortex (~50%,
P < 0.001) and significantly lower COX labelling inten-
sity (~20%, P < 0.05) in the hippocampus. These two
groups did not differ significantly in COX labelling area
in the hippocampus (P > 0.05).
Near-infrared mitigates amyloid pathology in APP/PS1
cortex
Along with NFTs, Aβ plaques are considered a primary
pathological hallmark of AD and Aβ load is often used
as a marker of AD severity [1,35]. We assessed the distri-
bution of Aβ plaques and more immature forms of the Aβpeptide in the neocortex and hippocampus of APP/PS1
mice aged 7 months; this age is after the first signs of
intracellular Aβ within cells (at 3 months; Figure 1G) and
extracellular Aβ plaques (at 4.5 and 12 months; Figure 1H
and 1I, respectively).
Three quantitative measures of plaque pathology were
used: percentage plaque burden, average plaque size and
number of plaques. Immunohistochemical labelling with
the anti-Aβ antibody 4G8 revealed a significant reduction
in percentage plaque burden (Figure 6A,D), average plaque
size (Figure 6B,E) and number of plaques (Figure 6C,F) in
both the neocortex and the hippocampus of NIr-treated
APP/PS1 mice relative to untreated APP/PS1 controls.
Percentage plaque burden was reduced by over 40% in the
neocortex (Figure 6A; P < 0.001) and over 70% in the
hippocampus (Figure 6D; P < 0.01), average plaque size was
reduced 25% in the neocortex (Figure 6B) and 30% in the
hippocampus (Figure 6E), and the number of plaques was
reduced by over 20% in the neocortex (Figure 6C) and by
over 55% in the hippocampus (Figure 6F; all P < 0.05).
The photomicrographs of the 4G8 immunoreactivity in
Figure 6 reflect the quantitative data described earlier. The
WT brain is free of plaques (Figure 6H,K); many 4G8+ pla-
ques (arrows) are present in the neocortex (Figure 6I) and
the hippocampus (Figure 6L) of untreated APP/PS1 mice,
and fewer plaques are present in NIr-treated APP/PS1 mice
(Figure 6J,M). Comparable immunolabelling was achieved
using the 6E10 anti-Aβ antibody (data not shown).
A similar but less pronounced trend was observed when
staining with Congo red (Figure 7), which stains only ma-
ture plaques. Mean counts of plaques in the neocortex
(Figure 7A) and the hippocampus (Figure 7B) of NIr-
treated APP/PS1 brains were lower than mean counts in
untreated APP/PS1 brains (reductions >30%). However,
the differences did not reach statistical significance; given
the findings described above with the 4G8 and 6E10 anti-
Aβ antibodies, this suggests that NIr may have greatest
effect on recently formed Aβ deposits. The micrographs
in Figure 7 show that mature plaques were absent from
the WT brain (Figure 7C,D) but were present in the neo-
cortex (Figure 7E) and hippocampus (Figure 7F) of un-
treated APP/PS1 brains. There appeared to be fewer
plaques in the NIr-treated APP/PS1 brains (Figure 7G,H).
Discussion
Using two mouse models with distinct AD-related path-
ologies (tau pathology in K3, amyloid pathology in APP/
PS1), we report evidence that NIr treatment can mitigate
the pathology characteristic of AD as well as reduce oxida-
tive stress and restore mitochondrial function in brain re-
gions affected early in the disease. Further, the extent of
mitigation – to levels less than at the start of treatment –
suggests that NIr can reverse some elements of AD-
related pathology.
Figure 5 Effect of near-infrared light treatment on cytochrome c oxidase labelling in the neocortex and hippocampus of K3 mice.
(A), (B), (F), (G) Quantification of immunolabelling of the mitochondrial marker cytochrome c oxidase (COX) in the neocortex retrosplenial area
(A, B) and hippocampal CA1 layer (F, G), based on average labelling intensity (A, F) and labelled area (B, G). All error bars indicate standard error
of the mean. *P < 0.05, ***P < 0.001. (C), (D), (E), (H), (I), (J) Representative micrographs of COX (red) labelling in the neocortex retrosplenial area
(C, D, E) and hippocampal CA1 layer (H, I, J). Nuclei were labelled with bisbenzimide (blue). Scale bar = 50 μm; scale in (J) applies to all other
micrographs. NIr, near-infrared light; WT, wildtype.
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Figure 6 Effect of near-infrared light on amyloid-beta and plaque pathology in APP/PS1 mice. (A), (B), (C), (D), (E), (F) Quantification of
amyloid-beta (Aβ) 4G8 immunolabelling of amyloid plaques in the neocortex (A, B, C) and hippocampus (D, E, F), based on plaque burden (A, D),
plaque size (B, E) and number of plaques (C, F). All error bars indicate standard error of the mean. *P < 0.05, ***P < 0.001, ****P < 0.0001. (H), (I), (J), (K),
(L), (M) Representative micrographs showing Aβ labelling with the 4G8 antibody (brown) in the neocortex (H, I, J) and hippocampus (K, L, M). Arrows
indicate plaques. Scale bar = 100 μm; scale in (M) applies to all other micrographs. DG, dentate gyrus of hippocampus; NIr, near-infrared light; SLM,
stratum lacunosum moleculare; WT, wildtype.
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induced neuroprotection in models of toxin-induced acute
neurodegeneration (that is, MPTP-induced parkinsonism).
When incorporated into the growing body of evidence
that NIr can also protect against CNS damage in models
of stroke, traumatic brain injury and retinal degeneration
[9-12,36], the findings provide a basis for trialling NIr
treatment as a strategy for protection against neurodegen-
eration from a range of causes. Present evidence is based
on the use of multiple methods, immunohistochemical
and histological, to demonstrate pathological features
(for example, 4G8 antibody labelling and Congo red
staining for amyloid plaques, AT8 antibody labelling
and Bielschowsky silver staining for NFTs).
Relationship to previous studies
The present study focused on pathological features con-
sidered characteristic of AD, as well as on signs of cellu-
lar damage (for example, oxidative stress, mitochondrial
dysfunction) that have been demonstrated in AD and in
animal models [2-4]. Our observations in the K3 strain
add to previous studies by providing the first evidence in
this strain of extensive oxidative damage and mitochon-
drial dysfunction [27].Our findings are consistent with previous reports of
the effects of red to infrared light on AD pathology in
animal models. De Taboada and colleagues assessed the
capacity of 808 nm laser-sourced infrared radiation, de-
livered three times per week over 6 months, to reduce
pathology in an APP transgenic model of Aβ amyloidosis
[17]. Treatment led to a reduction in plaque number,
amyloid load and inflammatory markers, an increase in
ATP levels and mitochondrial function, and mitigation
of behavioural deficits. De Taboada and colleagues com-
menced treatment at 3 months of age, before the ex-
pected onset of amyloid pathology and cognitive effects.
Similarly, Grillo and colleagues reported that 1,072 nm
infrared light, applied 4 days per week for 5 months,
reduces AD-related pathology in another APP/PS1 trans-
genic mouse model (TASTPM) [16]. These investigators
also initiated light treatment before the onset of pathology,
at 2 months of age. Both studies thus provide evidence
that infrared radiation can slow the progression of cerebral
degeneration in these models. The present results confirm
these observations, in two distinct transgenic strains; they
also confirm that the wound-healing and neuroprotective
effects of red-infrared length do not vary qualitatively with
wavelength, over a wide range.
Figure 7 Effect of near-infrared light on Congo red-positive plaque numbers in APP/PS1 mice. (A), (B) Quantification of Congo red-positive
plaque counts in the neocortex (A) and hippocampus (B). All error bars indicate standard error of the mean. (C), (D), (E), (F), (G), (H) Representative
micrographs showing Congo red staining of plaques in the neocortex (C, E, G) and hippocampus (D, F, H). Arrows indicate plaques. Scale bar = 50 μm;
scale in (H) applies to all other micrographs. DG, dentate gyrus of hippocampus; NIr, near-infrared light; SLM, stratum lacunosum moleculare; WT, wildtype.
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Previous reports have described the natural history of
the K3 [21,22] and APP/PS1 transgenic models [24,37].
Based on these previous reports and our own baseline
data (Figure 1), significant brain pathology and func-
tional deficits are present in both models at the ages
when we commenced treatment. Our results therefore
suggest that significant reversal of pathology has been
induced by the NIr treatment. This has implications for
clinical practice, where most patients are not diagnosed
until pathogenic mechanisms have already been initiated
and resultant neurologic symptoms manifest [15,27].
This evidence that AD-related neuropathology can be
transient – appear then disappear – is not novel. Garcia-Alloza and colleagues described evidence of the transient
deposition of Aβ, including the formation of plaque-like
structures, in a transgenic model of Aβ deposition [24].
Reversal of such pathology, by interventions such as NIr
treatment, may therefore be possible. However our results
suggest that reversal may also be limited to recently
formed, immature plaques, as we observed a significant
NIr-induced reduction in immunolabelling with the 4G8
and 6E10 antibodies but no significant difference in Congo
red staining. Because the 4G8 and 6E10 antibodies recog-
nise various forms of Aβ, while Congo red stains only ma-
ture, compacted plaques, a reasonable deduction is that
NIr treatment reduces only the transient, recently formed
Aβ deposits, with no substantial effect on mature plaques.
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different forms of Aβ, it is unclear how this might impact
on the therapeutic potential of NIr in a clinical setting.
Mechanisms
The mechanisms underlying the neuroprotective actions
of red to infrared light are not completely understood.
There is considerable evidence that NIr photobiomodula-
tion enhances mitochondrial function and ATP synthesis
by activating photoacceptors such as COX and increasing
electron transfer in the respiratory chain, while also re-
ducing harmful reactive oxygen species [38-40]. NIr
photobiomodulation could also upregulate protective
factors such as nerve growth factor and vascular endothe-
lial growth factor [41,42] and mesenchymal stem cells [43]
that could target specific areas of degeneration.
The ability of NIr to reduce the expression of hyper-
phosphorylated tau, which in turn reduces oxidative
stress [44], may be key to its neuroprotective effect. Oxi-
dative stress and free radicals increase the severity of
cerebrovascular lesions [45,46], mitochondrial dysfunc-
tion [4,47], oligomerisation of Aβ [5,48] and tauopathies
and cell death [48,49] in AD. Considering the brain’s
high consumption of oxygen and consequent susceptibil-
ity to oxidative stress, mitigating such stressors would
probably have a pronounced protective effect [50].
Conclusions
Overall, our results in two transgenic mouse models
with existing AD-related pathology suggest that low-
energy NIr treatment can reduce characteristic path-
ology, oxidative stress and mitochondrial dysfunction in
susceptible regions of the brain. These results, when
taken together with those in other models of neurode-
generation, strengthen the notion that NIr is a viable
neuroprotective treatment for a range of neurodegenerative
conditions. We believe this growing body of work provides
the impetus to begin trialling NIr treatment as a broad-
based therapy for AD and other neurodegenerations.
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